search
Back to results

Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Other
Other
Sponsored by
Institut de Recherches Internationales Servier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes mellitus, Phase 1, Healthy volunteers, Clinical translational exploratory study, Target involvement, Exploratory biomarkers, Cardiovascular disease, Vascular function, Coronary flow reserve, Biopterins, Cutaneous blood flow

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Healthy volunteers:

  • Age [18 -30], [50-59] and [60-70] years
  • Male and female healthy volunteers, except with skin types 5 and 6
  • Body weight ≥ 50 kg and BMI between [18.0 -28.0] kg/m^2 inclusive
  • Non or ex-smokers (defined as someone who completely stopped smoking for at least 1 month before the beginning of this study)
  • No clinically relevant findings in the medical history and physical examination, especially with regards to cardiovascular system, lung, liver and renal function
  • Normal blood and urine laboratory tests

Patients with type 2 diabetes (T2D) mellitus:

  • Male and female patients, except with skin types 5 and 6
  • Age [50 - 70] years
  • BMI ≤35 kg/m2
  • T2D patients (according to American Diabetes Association (ADA) criteria i.e. HbA1c > 6.5% or fasting plasma glucose > 126 mg/dL (7.00 mmol/L) or 2-hour glucose ≥ 200mg/dL (11.1mmol/L) after 75g oral glucose or glucose ≥200mg/dL (11.1mmol/L) at any time on two separate occasions (historic values and/or at selection)
  • Currently treated with Standards of Medical Care in T2D at stable doses for at least 3 months
  • Antihypertensive drugs allowed except beta-blockers and calcium antagonists
  • Non or ex-smokers (defined as someone who completely stopped smoking for at least 1 month before the beginning of this study)

Non inclusion Criteria:

Healthy volunteers:

  • Unlikely to co-operate in the study,
  • Participation in another interventional study, including last study drug intake, at the same time or within the 3 months preceding the selection visit; participation in non-interventional registries or epidemiological studies is allowed,
  • Deprived of his freedom by administrative or court order or under guardianship,
  • History or evidence of acute or chronic abuse of alcohol consumption of> 21 alcohol units per week for males and >14 units per week for females (1 alcohol unit = 100 mL of 12% wine; = 30 mL of 40% spirits; = 250 mL of 6% beer),
  • Positive alcohol breath test,
  • Positive cotinine test,
  • Known or suspected to be drug-dependent,
  • Positive result in urinary screening for drug abuse,
  • Pregnancy, breastfeeding or lactating,
  • Regular use of prescribed and non-prescribed drugs in the last 60 days before the day of investigations into the study except hormonal contraception (e.g. pill or hormonal intrauterine device (IUD) or hormonal implants or Nuva Ring) (if applicable),
  • Any drug intake of prescribed or non-prescribed drugs including over-counter drugs (except acetaminophen), herbal remedies or nutritional supplements such as multivitamins in the 2 weeks before the day of investigations unless the investigator deems this drug intake to be irrelevant for the purpose of this study and that can be temporarily suspended,
  • Intake of dipyridamol (contraindicated with adenosine infusion)
  • Known hypersensitivity to adenosine injection,
  • Any acute or chronic illness or clinically relevant findings (i.e. liver, kidney, cardiovascular diseases) in the selection visit examinations,

Patients with type II diabetes mellitus (T2D):

  • Unlikely to co-operate in the study,
  • Participation in another interventional study, including last study drug intake, at the same time or within the 3 months preceding the selection visit; participation in non-interventional registries or epidemiological studies is allowed,
  • Deprived of his freedom by administrative or court order or under guardianship,
  • Unwilling to allow his or her primary care practitioner to be notified of participation in the study and for information on a participant's medical history to be obtained from the general practitioner,
  • History or evidence of acute or chronic abuse of alcohol consumption of> 21 alcohol units per week for males and >14 units per week for females (1 alcohol unit = 100 mL of 12% wine; = 30 mL of 40% spirits; = 250 mL of 6% beer),
  • Positive alcohol breath test,
  • Positive cotinine test,
  • Known or suspected to be drug-dependent,
  • Positive result in urinary screening for drug abuse,
  • Pregnancy, breastfeeding or lactating,
  • Intake of dipyridamol (contraindicated with adenosine infusion)
  • Known hypersensitivity to adenosine injection,
  • Any acute or chronic illness or clinically relevant findings (i.e. liver,kidney, cardiovascular diseases) in the selection visit examinations.

Sites / Locations

  • Nuvisan GmbH

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Other

Other

Other

Other

Arm Label

Healthy volunteers aged of 18-30 years

Healthy volunteers aged of 50-59 years

Healthy volunteers aged of 60-70 years

Type 2 diabetic patients aged of 50-70 years

Arm Description

Outcomes

Primary Outcome Measures

Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Plasma/platelet levels of Dihydrobiopterin (BAH)/Tetrahydrobiopterin (BH4), Cyclic guanosine monophosphate (cGMP)
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Blood flow changes for vascular endothelial function
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Coronary flow reserve
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Genomic market (blood) DNA and/or RNA characteristics of genes such as GTP Cyclohydrolase 1 (GCH)

Secondary Outcome Measures

Adverse events
Occurence of any adverse events
Blood pressure supine
Relevant abnormalities on supine blood pressure

Full Information

First Posted
January 27, 2021
Last Updated
November 30, 2021
Sponsor
Institut de Recherches Internationales Servier
Collaborators
ADIR, a Servier Group company
search

1. Study Identification

Unique Protocol Identification Number
NCT04744636
Brief Title
Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus
Official Title
Target Involvement and Exploratory Biomarkers Investigations in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
April 3, 2017 (Actual)
Primary Completion Date
September 15, 2018 (Actual)
Study Completion Date
September 15, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut de Recherches Internationales Servier
Collaborators
ADIR, a Servier Group company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the vascular function and biomarkers in healthy volunteers and type 2 diabetic patients.
Detailed Description
The present interventional study will be performed in 3 groups of healthy volunteers of different ages and in type 2 diabetic patients without an investigational medicinal product administrated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes mellitus, Phase 1, Healthy volunteers, Clinical translational exploratory study, Target involvement, Exploratory biomarkers, Cardiovascular disease, Vascular function, Coronary flow reserve, Biopterins, Cutaneous blood flow

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy volunteers aged of 18-30 years
Arm Type
Other
Arm Title
Healthy volunteers aged of 50-59 years
Arm Type
Other
Arm Title
Healthy volunteers aged of 60-70 years
Arm Type
Other
Arm Title
Type 2 diabetic patients aged of 50-70 years
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
Other
Intervention Description
Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2. Then, subjects will be discharged at the end of the last investigation day (Day 2). All the participants have received two pharmacological agents (NIMP) : Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function. Adenosine : administered intravenously during MRI for the measurement of CFR.
Intervention Type
Drug
Intervention Name(s)
Other
Intervention Description
Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2. Then, subjects will be discharged at the end of the last investigation day (Day 2). All the participants have received two pharmacological agents (NIMP): Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function. Adenosine : administered intravenously during MRI for the measurement of CFR.
Primary Outcome Measure Information:
Title
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Description
Plasma/platelet levels of Dihydrobiopterin (BAH)/Tetrahydrobiopterin (BH4), Cyclic guanosine monophosphate (cGMP)
Time Frame
Day 1
Title
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Description
Blood flow changes for vascular endothelial function
Time Frame
Day 1
Title
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Description
Coronary flow reserve
Time Frame
Day 2
Title
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
Description
Genomic market (blood) DNA and/or RNA characteristics of genes such as GTP Cyclohydrolase 1 (GCH)
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Adverse events
Description
Occurence of any adverse events
Time Frame
Through study completion, 3.5 weeks
Title
Blood pressure supine
Description
Relevant abnormalities on supine blood pressure
Time Frame
Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers: Age [18 -30], [50-59] and [60-70] years Male and female healthy volunteers, except with skin types 5 and 6 Body weight ≥ 50 kg and BMI between [18.0 -28.0] kg/m^2 inclusive Non or ex-smokers (defined as someone who completely stopped smoking for at least 1 month before the beginning of this study) No clinically relevant findings in the medical history and physical examination, especially with regards to cardiovascular system, lung, liver and renal function Normal blood and urine laboratory tests Patients with type 2 diabetes (T2D) mellitus: Male and female patients, except with skin types 5 and 6 Age [50 - 70] years BMI ≤35 kg/m2 T2D patients (according to American Diabetes Association (ADA) criteria i.e. HbA1c > 6.5% or fasting plasma glucose > 126 mg/dL (7.00 mmol/L) or 2-hour glucose ≥ 200mg/dL (11.1mmol/L) after 75g oral glucose or glucose ≥200mg/dL (11.1mmol/L) at any time on two separate occasions (historic values and/or at selection) Currently treated with Standards of Medical Care in T2D at stable doses for at least 3 months Antihypertensive drugs allowed except beta-blockers and calcium antagonists Non or ex-smokers (defined as someone who completely stopped smoking for at least 1 month before the beginning of this study) Non inclusion Criteria: Healthy volunteers: Unlikely to co-operate in the study, Participation in another interventional study, including last study drug intake, at the same time or within the 3 months preceding the selection visit; participation in non-interventional registries or epidemiological studies is allowed, Deprived of his freedom by administrative or court order or under guardianship, History or evidence of acute or chronic abuse of alcohol consumption of> 21 alcohol units per week for males and >14 units per week for females (1 alcohol unit = 100 mL of 12% wine; = 30 mL of 40% spirits; = 250 mL of 6% beer), Positive alcohol breath test, Positive cotinine test, Known or suspected to be drug-dependent, Positive result in urinary screening for drug abuse, Pregnancy, breastfeeding or lactating, Regular use of prescribed and non-prescribed drugs in the last 60 days before the day of investigations into the study except hormonal contraception (e.g. pill or hormonal intrauterine device (IUD) or hormonal implants or Nuva Ring) (if applicable), Any drug intake of prescribed or non-prescribed drugs including over-counter drugs (except acetaminophen), herbal remedies or nutritional supplements such as multivitamins in the 2 weeks before the day of investigations unless the investigator deems this drug intake to be irrelevant for the purpose of this study and that can be temporarily suspended, Intake of dipyridamol (contraindicated with adenosine infusion) Known hypersensitivity to adenosine injection, Any acute or chronic illness or clinically relevant findings (i.e. liver, kidney, cardiovascular diseases) in the selection visit examinations, Patients with type II diabetes mellitus (T2D): Unlikely to co-operate in the study, Participation in another interventional study, including last study drug intake, at the same time or within the 3 months preceding the selection visit; participation in non-interventional registries or epidemiological studies is allowed, Deprived of his freedom by administrative or court order or under guardianship, Unwilling to allow his or her primary care practitioner to be notified of participation in the study and for information on a participant's medical history to be obtained from the general practitioner, History or evidence of acute or chronic abuse of alcohol consumption of> 21 alcohol units per week for males and >14 units per week for females (1 alcohol unit = 100 mL of 12% wine; = 30 mL of 40% spirits; = 250 mL of 6% beer), Positive alcohol breath test, Positive cotinine test, Known or suspected to be drug-dependent, Positive result in urinary screening for drug abuse, Pregnancy, breastfeeding or lactating, Intake of dipyridamol (contraindicated with adenosine infusion) Known hypersensitivity to adenosine injection, Any acute or chronic illness or clinically relevant findings (i.e. liver,kidney, cardiovascular diseases) in the selection visit examinations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Denis Strugala, Dr
Organizational Affiliation
Nuvisan GmbH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nuvisan GmbH
City
Neu-Ulm
ZIP/Postal Code
89231
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD Sharing Time Frame
After Marketing Authorisation in EEA or US if the study is used for the approval.
IPD Sharing Access Criteria
Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
IPD Sharing URL
https://clinicaltrials.servier.com/
Links:
URL
https://clinicaltrials.servier.com/wp-content/uploads/CL1-RTCMP-001-anonymisedsynopsis-2020.03.13.pdf
Description
Results summary
Available IPD and Supporting Information:
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
https://clinicaltrials.servier.com/
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
https://clinicaltrials.servier.com/
Available IPD/Information Type
Statistical Analysis Plan
Available IPD/Information URL
https://clinicaltrials.servier.com/
Available IPD/Information Type
Informed Consent Form
Available IPD/Information URL
https://clinicaltrials.servier.com/
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
https://clinicaltrials.servier.com/
Available IPD/Information Type
Study-level clinical trial data
Available IPD/Information URL
https://clinicaltrials.servier.com/

Learn more about this trial

Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs